Alligators Bioscience's portfolio comprise the drug candidates mitazalimab, ATOR-1017 and ALG.APV-527, as well as the drug concept Neo-X-Prime™, all of which are intended for the treatment of metastatic cancers. The project AC101 (HLX22) is run by a partner, the Chinese company Shanghai Henlius Biotech Inc., who are responsible for financing and operating its clinical development.